Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).

JOURNAL ARTICLE published 10 June 2022 in Journal of Clinical Oncology

Authors: Giovanni Scambia | Francesco Raspagliesi | Giorgio Valabrega | Nicoletta Colombo | Carmen Pisano | Chiara Cassani | Germana Tognon | Stefano Tamberi | Giorgia Mangili | Serafina Mammoliti | Ugo De Giorgi | Filippo Greco | Anna Maria Mosconi | Enrico Breda | Grazia Artioli | Claudia Andreetta | Claudia Casanova | Rita Ceccherini | Antonio Frassoldati | Domenica Lorusso